Quinoxalinylurea derivatives as a novel class of JSP-1 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 8, 2007, Pages 2118-2122

  Zhang, Li ^a   Qiu, Beiying ^b   Xiong, Bing ^a   Li, Xin ^a   Li, Jingya ^b   Wang, Xin ^a   Li, Jia ^b   Shen, Jingkang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b National Center for Drug Screening   (China)

Author keywords

Inhibitor; JSP 1; Quinoxalinylurea

Indexed keywords

2 FURYL N ETHYLBUTYLAMINE; 2 FURYL N METHYLBUTYLAMINE; 2 FURYL TERT BUTYLAMINE; 2 FURYLBUTYLAMINE; 2 FURYLCYCLOPENTYLAMINE; 2 FURYLDIETHYLAMINE; 2 FURYLDIMETHYLAMINE; 2 FURYLDIPROPYLAMINE; 2 FURYLETHYLAMINE; 2 FURYLISOBUTYLAMINE; 2 FURYLISOPROPYLAMINE; 2 FURYLPIPERIDINE; 2 FUTYLCYCLOHEXYLAMINE; 4 BROMOPHENYLDIETHYLAMINE; 4 BROMOPHENYLPYRROLIDINE; 4 FLUOROPHENYLCYCLOHEXYLAMINE; 4 FLUOROPHENYLDIETHYLAMINE; 4 METHYLPHENYLCYCLOPENTYLAMINE; 4 METHYLPHENYLDIETHYLAMINE; METHOXYCYCLOHEXYLAMINE; METHOXYPIPERIDINE; PHENYLDIETHYLAMINE; PHENYLPIPERIDINE; PHOSPHOPROTEIN PHOSPHATASE; QUINOXALINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE STIMULATORY PHOSPHATASE 1; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; BIOASSAY; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG SCREENING; INFLAMMATORY DISEASE; MATHEMATICAL MODEL; METABOLIC DISORDER; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VASCULAR DISEASE;

ALLOSTERIC SITE; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 33947585924     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.094     Document Type: Article

References (26)

1. Shen Y., Luche R., Wei B., Gordon M.L., Diltz C.D., and Tonks N.K. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13613
2. Alonso A., Merlo J.J., Na S.Q., Kholod N., Jaroszewski L., Kharitonenkov A., Williams S., Godzik A., Posada J.D., and Mustelin T. J. Biol. Chem. 277 (2002) 5524
3. Chen A.J., Zhou G.S., Juan T., Colicos S.M., Cannon J.P., Cabriera-Hansen M., Meyer C.F., Jurecic R., Copeland N.G., Gilbert D.J., Jenkins N.A., Fletcher F., Tan T.H., and Belmont J.W. J. Biol. Chem. 277 (2002) 36592
4. Alonso A., Rojas A., Godzik A., and Mustelin T. In: Arino J., and Alexander D.R. (Eds). Top. Curr. Genetics Vol. 5 (2004), Springer-Verlag, Berlin, Heidelberg 333
5. Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., and Mustelin T. Cell 117 (2004) 699
6. van Huijsduijnen R.H., Bombrun A., and Swinnen D. Drug Discovery Today 7 (2002) 1013
7. Hoffman B.T., Nelson M.R., Burdick K., and Baxter S.M. Curr. Pharm. Des. 10 (2004) 1161
8. Davis R.J. Cell 103 (2000) 239
9. Manning A.M., and Davis R.J. Nat. Rev. Drug Disc. 2 (2003) 554
10. Cutshall N.S., O'Day C., and Prezhdo M. Bioorg. Med. Chem. Lett. 15 (2005) 3374
11. Makino K., Sakata G., Morimoto K., and Ochiai Y. Heterocycles 23 (1985) 2025
12. Siddiqui A.A., Khan S.A., and Bhatt S. Asian J. Chem. 14 (2002) 1109
13. Kim K.S., Qian L.G., Dickinson K.E.J., Delaney C.L., Bird J.E., Waldron T.L., and Moreland S. Bioorg. Med. Chem. Lett. 3 (1993) 2667
14. Kim K.S., Qian L.G., Bird J.E., Dickinson K.E.J., Moreland S., Schaeffer T.R., Waldron T.L., Delaney C.L., Weller H.N., and Miller A.V. J. Med. Chem. 36 (1993) 2335
15. Takano Y., Shiga F., Asano J., Ando N., Uchiki H., and Anraku T. Bioorg. Med. Chem. Lett. 13 (2003) 3521
16. Catarzi D., Colotta V., Varano F., Calabri F.R., Filacchioni G., Galli A., Costagli C., and Carla V. J. Med. Chem. 47 (2004) 262
17. Alamino, R. J. U.S. Patent 4,540,693, 1985; Chem. Abstr. 1986, 104, 88601.
18. Abdel-Jalil R.J., Al-Qawasmeh R.A., Voelter W., Heeg P., El-Abadelah M.M., and Sabri S.S. J. Heterocycl. Chem. 37 (2000) 1273
19. Katoh A., Takahashi M., and Ohkanda J. Chem. Lett. (1996) 369
20. Cheeseman G.W.H. J. Chem. Soc. (1962) 1170
21. Cotarca L., Delogu P., Nardelli A., and Sunjic V. Synthesis (1996) 553
22. 50/[I])k}, where k is the Hill coefficient. For mechanism studies, data were analyzed using a nonlinear regression fit according to classical Michaelis-Menten kinetics models.
23. The reversibility of inhibition is easily determined by measuring the recovery of enzymatic activity after dialysis of the enzyme-inhibitor complex against assays. To test for reversibility, excessive compounds A4 and A17 were incubated with 100 nM enzyme. Then the mixture was dialyzed against the assay buffer and the activity of the enzyme was tested in different times. If the inhibitor was reversible, enzymatic activity could recover to some extent; and if the inhibitor was irreversible, enzymatic activity could not recover at any time. Figure 2 shows the activity of JSP-1 was recovered to some extent after dialysis, compared with the mixture without dialysis. It verified that compounds A4 and A17 were reversible JSP-1 inhibitors.
24. Wiesmann C., Barr K.J., Kung J., Zhu J., Erlanson D.A., Shen W., Fahr B.J., Zhong M., Taylor L., Randal M., McDowell R.S., and Hansen S.K. Nat. Struct. Mol. Biol. 11 (2004) 730
25. Yokota T., Nara Y., Kashima A., Matsubara K., Misawa S., Kato R., and Sugio S. Proteins 66 (2007) 272
26. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comput. Chem. 19 (1998) 1639